El Paso, TX -- (SBWire) -- 01/20/2015 --Premier Biomedical, Inc. (BIEI) announced that they intend to nationally sell an exclusively licensed and patented drug treatment for fibromyalgia. Premier is submitting documents to the Food and Drug Administration to discuss agency requirements for both clinical studies and eventual marketing approval for this patented drug combination. The drug, Feldetrex®, was issued a patent for its unique combination of FDA approved compounds, in October of 2014.
Feldetrex® is designed to treat the symptoms of fibromyalgia, and will compete with several name brand drugs whose combined annual sales exceed $10 billion. Premier Biomedical has obtained exclusive rights to the Feldetrex® patent.
Premier Biomedical's President & CEO, William A. Hartman, stated that, "This is our second, in a series of filings, we have made with the FDA. Those suffering from fibromyalgia know how painful, debilitating and frustrating it can be to try and manage the symptoms of this widespread disease. We look forward to completing the FDA regulatory process, so that we can get our products into this vast market, and relieve suffering as soon as possible. We intend to capture a share of this ten billion dollar annual market."
"We are very excited about this drug's ability to relieve the symptoms of fibromyalgia, without many of the negative side-effects associated with many of the current drug treatments," said Mitchell S. Felder, M.D., Premier Biomedical's chair of the scientific advisory board.
About Premier Biomedical, Inc.
Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP). The company's R&D efforts are centered in El Paso, TX and their business offices are in Western Pennsylvania. The Company's common stock trades on the fully reporting Over-The-Counter Bulletin Board under the ticker symbol "BIEI." http://www.premierbiomedicalinc.com/
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.
Contact:
Premier Biomedical, Inc.
W. Hartman, 724-633-7033
info@premierbiomedicalinc.com
Source: UPTICK Newswire
Premier Biomedical Files Initial FDA Submission for Fibromyalgia Treatment